Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNC1
Period2020-01-01 → 2020-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100L1LQ.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥314m2020-01-01 → 2020-12-31StandaloneNet sales
Revenue¥1.3bn2019-01-01 → 2019-12-31StandaloneNet sales
Revenue¥169m2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Revenue¥229m2017-01-01 → 2017-12-31dStandaloneNet sales (5-year summary)
Revenue¥178m2016-01-01 → 2016-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.7bn2020-01-01 → 2020-12-31StandaloneOperating income
Operating income−¥511m2019-01-01 → 2019-12-31StandaloneOperating income
Ordinary income−¥1.7bn2020-01-01 → 2020-12-31StandaloneOrdinary income
Ordinary income−¥539m2019-01-01 → 2019-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥864m2016-01-01 → 2016-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥2.1bn2020-01-01 → 2020-12-31StandaloneIncome before income taxes
Profit before tax−¥909m2019-01-01 → 2019-12-31StandaloneIncome before income taxes
Net income−¥2.1bn2020-01-01 → 2020-12-31StandaloneProfit loss
Net income−¥912m2019-01-01 → 2019-12-31StandaloneProfit loss
Net income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet income loss (5-year summary)
Net income−¥931m2016-01-01 → 2016-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.8bnat 2020-12-31StandaloneAssets
Total assets¥4.4bnat 2019-12-31StandaloneAssets
Total assets¥3.4bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.5bnat 2017-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.1bnat 2016-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥793mat 2020-12-31StandaloneLiabilities
Total liabilities¥926mat 2019-12-31StandaloneLiabilities
Net assets / equity¥2.0bnat 2020-12-31StandaloneNet assets
Net assets / equity¥3.5bnat 2019-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2018-12-31dStandaloneNet assets
Net assets / equity¥2.9bnat 2017-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.6bnat 2016-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.1bnat 2020-12-31StandaloneCash and deposits
Cash and deposits¥3.3bnat 2019-12-31StandaloneCash and deposits
Cash & equivalents¥1.8bnat 2020-12-31StandaloneCash and cash equivalents
Cash & equivalents¥3.1bnat 2019-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2018-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.9bnat 2017-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.4bnat 2016-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.5bn2020-01-01 → 2020-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥238m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥903m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥38m2020-01-01 → 2020-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥4m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥342m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥132m2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥257m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥242m2020-01-01 → 2020-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2019-01-01 → 2019-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥6m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-145.582020-01-01 → 2020-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-65.552019-01-01 → 2019-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-104.552018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥136.43at 2020-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥240.71at 2019-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥216.61at 2018-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥263.54at 2017-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio71.4%at 2020-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.7%at 2019-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio84.3%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.9%at 2017-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued14,641,900at 2020-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued14,331,300at 2019-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued13,346,000at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued11,086,000at 2017-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees32at 2020-12-31StandaloneNumber of employees
Employees27at 2019-12-31StandaloneNumber of employees
Employees30at 2018-12-31dStandaloneNumber of employees
Employees29at 2017-12-31dStandaloneNumber of employees
Employees30at 2016-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 43
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2020-01-01 → 2020-12-31¥3m
Reconciling Itemsreconcilingdepreciation2020-01-01 → 2020-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2020-12-31¥2.7bn
Reconciling Itemsreconcilingsegment profit2020-01-01 → 2020-12-31−¥888m
Diagnostic Divisionreportable segmentcapex2020-01-01 → 2020-12-31¥14m
Diagnostic Divisionreportable segmentdepreciation2020-01-01 → 2020-12-31¥2m
Diagnostic Divisionreportable segmentemployeesat 2020-12-312 pure
Diagnostic Divisionreportable segmentrevenue2020-01-01 → 2020-12-31¥610,000
Diagnostic Divisionreportable segmentrevenue external2020-01-01 → 2020-12-31¥610,000
Diagnostic Divisionreportable segmentsegment assetsat 2020-12-31¥22m
Diagnostic Divisionreportable segmentsegment profit2020-01-01 → 2020-12-31−¥73m
Pharmaceutical Divisionreportable segmentemployeesat 2020-12-3112 pure
Pharmaceutical Divisionreportable segmentrevenue2020-01-01 → 2020-12-31¥314m
Pharmaceutical Divisionreportable segmentrevenue external2020-01-01 → 2020-12-31¥314m
Pharmaceutical Divisionreportable segmentsegment assetsat 2020-12-31¥91m
Pharmaceutical Divisionreportable segmentsegment profit2020-01-01 → 2020-12-31−¥713m
—segment totalemployeesat 2020-12-3114 pure
Total Of Reportable Segments And Otherssegment totalcapex2020-01-01 → 2020-12-31¥14m
Total Of Reportable Segments And Otherssegment totaldepreciation2020-01-01 → 2020-12-31¥2m
Total Of Reportable Segments And Otherssegment totalrevenue2020-01-01 → 2020-12-31¥314m
Total Of Reportable Segments And Otherssegment totalrevenue external2020-01-01 → 2020-12-31¥314m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2020-12-31¥113m
Total Of Reportable Segments And Otherssegment totalsegment profit2020-01-01 → 2020-12-31−¥787m
Reconciling Itemsreconcilingcapex2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingdepreciation2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2019-12-31¥3.9bn
Reconciling Itemsreconcilingsegment profit2019-01-01 → 2019-12-31−¥733m
Diagnostic Divisionreportable segmentcapex2019-01-01 → 2019-12-31¥10m
Diagnostic Divisionreportable segmentdepreciation2019-01-01 → 2019-12-31¥303,000
Diagnostic Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentsegment assetsat 2019-12-31¥10m
Diagnostic Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31−¥152m
Pharmaceutical Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentsegment assetsat 2019-12-31¥420m
Pharmaceutical Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31¥373m
Total Of Reportable Segments And Otherssegment totalcapex2019-01-01 → 2019-12-31¥10m
Total Of Reportable Segments And Otherssegment totaldepreciation2019-01-01 → 2019-12-31¥303,000
Total Of Reportable Segments And Otherssegment totalrevenue2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2019-12-31¥430m
Total Of Reportable Segments And Otherssegment totalsegment profit2019-01-01 → 2019-12-31¥221m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 952
ItemContextValueUnit
Dividends income noiCurrentYearDuration_NonConsolidatedMember3000JPY
Other noiPrior1YearDuration_NonConsolidatedMember217000JPY
Other noiCurrentYearDuration_NonConsolidatedMember－JPY
Non operating incomePrior1YearDuration_NonConsolidatedMember20457000JPY
Non operating incomeCurrentYearDuration_NonConsolidatedMember568000JPY
Interest expenses noePrior1YearDuration_NonConsolidatedMember3947000JPY
Interest expenses noeCurrentYearDuration_NonConsolidatedMember4170000JPY
Amortization of restricted stock remuneration noePrior1YearDuration_NonConsolidatedMember42108000JPY
Amortization of restricted stock remuneration noeCurrentYearDuration_NonConsolidatedMember13899000JPY
Issuance cost of subscription rights to shares noePrior1YearDuration_NonConsolidatedMember－JPY
Issuance cost of subscription rights to shares noeCurrentYearDuration_NonConsolidatedMember9641000JPY
Stock issuance cost noePrior1YearDuration_NonConsolidatedMember－JPY
Stock issuance cost noeCurrentYearDuration_NonConsolidatedMember4152000JPY
Foreign exchange losses noePrior1YearDuration_NonConsolidatedMember2115000JPY
Foreign exchange losses noeCurrentYearDuration_NonConsolidatedMember17556000JPY
Other noePrior1YearDuration_NonConsolidatedMember－JPY
Other noeCurrentYearDuration_NonConsolidatedMember32000JPY
Non operating expensesPrior1YearDuration_NonConsolidatedMember48171000JPY
Non operating expensesCurrentYearDuration_NonConsolidatedMember49453000JPY
Ordinary incomePrior1YearDuration_NonConsolidatedMember-539177000JPY
Ordinary incomeCurrentYearDuration_NonConsolidatedMember-1723537000JPY
Bad debts written off elPrior1YearDuration_NonConsolidatedMember9818000JPY
Bad debts written off elCurrentYearDuration_NonConsolidatedMember35681000JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember－JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember11140000JPY
Loss on valuation of investment securities elPrior1YearDuration_NonConsolidatedMember359597000JPY
Loss on valuation of investment securities elCurrentYearDuration_NonConsolidatedMember321000000JPY
Extraordinary lossPrior1YearDuration_NonConsolidatedMember369415000JPY
Extraordinary lossCurrentYearDuration_NonConsolidatedMember367821000JPY
Income before income taxesPrior1YearDuration_NonConsolidatedMember-908593000JPY
Income before income taxesCurrentYearDuration_NonConsolidatedMember-2091359000JPY
Income taxes currentPrior1YearDuration_NonConsolidatedMember3752000JPY
Income taxes currentCurrentYearDuration_NonConsolidatedMember3727000JPY
Income taxesPrior1YearDuration_NonConsolidatedMember3752000JPY
Income taxesCurrentYearDuration_NonConsolidatedMember3727000JPY
Profit lossPrior1YearDuration_NonConsolidatedMember-912346000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember-2095087000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_CapitalStockMember6402658000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_LegalCapitalSurplusMember6395158000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_OtherCapitalSurplusMember－JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_CapitalSurplusMember6395158000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_RetainedEarningsBroughtForwardMember-9893863000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_RetainedEarningsMember-9893863000JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_TreasuryStockMember－JPY
Net assetsPrior2YearInstant_NonConsolidatedMember_ShareholdersEquityMember2903953000JPY
Issuance of new sharesPrior1YearDuration_NonConsolidatedMember_CapitalStockMember718615000JPY
Issuance of new sharesPrior1YearDuration_NonConsolidatedMember_LegalCapitalSurplusMember718615000JPY
Issuance of new sharesPrior1YearDuration_NonConsolidatedMember_CapitalSurplusMember718615000JPY
Issuance of new sharesPrior1YearDuration_NonConsolidatedMember_ShareholdersEquityMember1437231000JPY
Gain on disposal of treasury stockPrior1YearDuration_NonConsolidatedMember_OtherCapitalSurplusMember9650000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2019-12-31pass rounding
balance sheet identitynon_consolidated 2020-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2018-12-31pass
statement vs summary · net assetsnon_consolidated 2019-12-31pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · operating cash flownon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · operating cash flownon_consolidated 2020-01-01/2020-12-31pass
statement vs summary · revenuenon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · revenuenon_consolidated 2020-01-01/2020-12-31pass
statement vs summary · total assetsnon_consolidated 2019-12-31pass
statement vs summary · total assetsnon_consolidated 2020-12-31pass